Literature DB >> 17515861

RSV mediates Pseudomonas aeruginosa binding to cystic fibrosis and normal epithelial cells.

Bart E Van Ewijk1, Tom F W Wolfs, Piet C Aerts, Kok P M Van Kessel, Andre Fleer, Jan L L Kimpen, Cornelis K Van der Ent.   

Abstract

Cystic fibrosis lung disease typically has a course of exacerbations and remissions, suggesting that external factors like viral infections can influence this course. Clinical data suggest synergism between respiratory syncytial virus (RSV) infections and Pseudomonas aeruginosa in cystic fibrosis (CF) lung disease. We studied the influence of RSV infection on adherence of P. aeruginosa to IB3-1, HEp-2, and A549 epithelial cell monolayers in vitro. RSV infection of epithelial cells as well as simultaneous addition of RSV and P. aeruginosa to noninfected cells both strongly enhanced the pseudomonal adherence to epithelial cells. The increased adherence varied from 1.2- to 8.2-fold in case of previous RSV infection, and from 1.7- to 16.1-fold in case of simultaneous addition. We observed direct binding of RSV to P. aeruginosa, and blocking of RSV with heparin eliminated the effect on increased adherence. This suggests that RSV possibly acts as a coupling agent between P. aeruginosa and epithelial cells. In conclusion, RSV enhances P. aeruginosa infection of respiratory epithelial cells. It suggests a role of specific viral-bacterial interactions in exacerbations of CF lung disease, which could have important implications on prevention and treatment.

Entities:  

Mesh:

Year:  2007        PMID: 17515861     DOI: 10.1203/pdr.0b013e3180332d1c

Source DB:  PubMed          Journal:  Pediatr Res        ISSN: 0031-3998            Impact factor:   3.756


  40 in total

1.  Cystic fibrosis and the war for iron at the host-pathogen battlefront.

Authors:  Nicole M Bouvier
Journal:  Proc Natl Acad Sci U S A       Date:  2016-01-22       Impact factor: 11.205

2.  A decade of respiratory syncytial virus epidemiology and prophylaxis: translating evidence into everyday clinical practice.

Authors:  Bosco A Paes; Ian Mitchell; Anna Banerji; Krista L Lanctôt; Joanne M Langley
Journal:  Can Respir J       Date:  2011 Mar-Apr       Impact factor: 2.409

3.  Palivizumab, pneumococcal and influenza vaccination in cystic fibrosis.

Authors:  Mukta Jain; Anne H Thomson
Journal:  J R Soc Med       Date:  2009-07       Impact factor: 5.344

4.  Cystic Fibrosis Foundation practice guidelines for the management of infants with cystic fibrosis transmembrane conductance regulator-related metabolic syndrome during the first two years of life and beyond.

Authors:  Drucy Borowitz; Richard B Parad; Jack K Sharp; Kathryn A Sabadosa; Karen A Robinson; Michael J Rock; Philip M Farrell; Marci K Sontag; Margaret Rosenfeld; Stephanie D Davis; Bruce C Marshall; Frank J Accurso
Journal:  J Pediatr       Date:  2009-12       Impact factor: 4.406

Review 5.  The airway epithelium: soldier in the fight against respiratory viruses.

Authors:  Marjolaine Vareille; Elisabeth Kieninger; Michael R Edwards; Nicolas Regamey
Journal:  Clin Microbiol Rev       Date:  2011-01       Impact factor: 26.132

Review 6.  Clinical significance of microbial infection and adaptation in cystic fibrosis.

Authors:  Alan R Hauser; Manu Jain; Maskit Bar-Meir; Susanna A McColley
Journal:  Clin Microbiol Rev       Date:  2011-01       Impact factor: 26.132

7.  Palivizumab prophylaxis in infants with cystic fibrosis does not delay first isolation of Pseudomonas aeruginosa or Staphylococcus aureus.

Authors:  Clélia Buchs; Marie-Laure Dalphin; Stéphane Sanchez; Marie Perceval; Laurianne Coutier; Catherine Mainguy; Behrouz Kassaï-Koupaï; Philippe Reix
Journal:  Eur J Pediatr       Date:  2017-05-16       Impact factor: 3.183

8.  Respiratory Syncytial Virus Prophylaxis in Special Populations: Is it Something Worth Considering in Cystic Fibrosis and Immunosuppression?

Authors:  William A Prescott; David J Hutchinson
Journal:  J Pediatr Pharmacol Ther       Date:  2011-04

9.  Direct interactions with influenza promote bacterial adherence during respiratory infections.

Authors:  Hannah M Rowe; Victoria A Meliopoulos; Amy Iverson; Perrine Bomme; Stacey Schultz-Cherry; Jason W Rosch
Journal:  Nat Microbiol       Date:  2019-05-20       Impact factor: 17.745

10.  Influenza vaccination among household contacts of children with cystic fibrosis and healthy children.

Authors:  Karen Kam; Athena McConnell
Journal:  Paediatr Child Health       Date:  2013-11       Impact factor: 2.253

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.